Articles related to CANCER CARE

In patients with cisplatin-eligible muscle-invasive bladder cancer, perioperative enfortumab vedotin plus pembrolizumab improved event-free and overall survival compared with standard neoadjuvant gemcitabine-cisplatin chemotherapy in the phase 3 KEYNOTE-B15 trial.

The FDA granted Fast Track designation in September 2026 to multiple investigational oncology agents and one prostate cancer imaging strategy, highlighting continued regulatory support for therapies targeting high unmet needs across solid tumors and hematologic malignancies.

A patient with advanced follicular lymphoma described a prolonged diagnostic journey marked by evolving symptoms, initial alternative diagnoses, urgent treatment initiation, and the psychological challenges that continued long after active therapy began.

The death of a 26-year-old woman diagnosed with metastatic cholangiocarcinoma at age 23 highlights challenges surrounding cancer recognition in younger adults, patient engagement through social media, and communication when treatment options become limited.

Radiation oncology practices report substantial revenue declines following 2026 CMS coding changes, with some centers citing reimbursement reductions of 15% to 30%. Stakeholders warn the financial pressures could affect treatment access, particularly in community and rural settings.

Artificial intelligence tools are increasingly being integrated into prostate cancer imaging, pathology, prognostication, and treatment planning. Although several platforms have demonstrated promising accuracy and workflow benefits, broad clinical adoption will require prospective validation, regulatory oversight, and careful implementation.